New hope for controlling breast cancer brain spread
NCT ID NCT05041842
Summary
This study is testing whether adding the drug tucatinib to standard treatments can better control breast cancer that has spread to the brain. It involves 53 adults with HER2-positive metastatic breast cancer whose cancer progressed in the brain but is stable elsewhere in the body. The goal is to see if this three-drug combination can delay cancer progression and improve survival after patients receive local brain treatment like radiation or surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER WITH A ISOLATED BRAIN PROGRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologi
Plérin, France
-
Centre Antoine Lacassagne
Nice, France
-
Centre Francois Baclesse
Caen, France
-
Centre Georges François Leclerc
Dijon, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Annecy Genevois
Pringy, France
-
Centre Hospitalier Universitaire de Tours
Tours, France
-
Centre Leon Berard
Lyon, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Gustave Roussy
Villejuif, France
-
Hôpital privé Jean Mermoz
Lyon, France
-
Institut Bergonié
Bordeaux, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Jean Godinot
Reims, France
-
Institut de Cancérologie de l'Ouest - Site Paul Papin
Angers, France
-
Institut du cancer de Montpellier
Montpellier, 34090, France
Conditions
Explore the condition pages connected to this study.